Person: ERDOĞAN, EZGİ BAŞAK
6 results
Search Results
Now showing 1 - 6 of 6
Publication Metadata only Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy(2015-08-01) ERGÜL, Nurhan; Kadioglu, HÜSEYİN; Yildiz, Seyma; YUCEL, Serap Baskaya; Gucin, ZÜHAL; Erdogan, EZGİ BAŞAK; Aydin, MEHMET; MUSLUMANOGLU, Mahmut; KADIOĞLU, HÜSEYİN; YILDIZ, ŞEYMA; GÜCİN, ZÜHAL; ERDOĞAN, EZGİ BAŞAK; AYDIN, MEHMETBackground: Non-invasive evaluation of the extent of axillary nodal involvement in early-stage breast cancer (ESBC) patients and accurate assessment of multifocality are both challenging. Few reports have explored whether 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) might be more useful than other diagnostic methods in these contexts.Publication Metadata only Evaluation of nasal mucociliary transport rate according to nasal septum deviation type(2016-07-01) Dogan, REMZİ; TUGRUL, Selahattin; Erdogan, EZGİ BAŞAK; Eren, SABRİ BAKİ; Ozturan, ORHAN; DOĞAN, REMZI; TUĞRUL, SELAHATTİN; ERDOĞAN, EZGİ BAŞAK; EREN, SABRİ BAKİ; ÖZTURAN, ORHANBackgroundNasal septum deviation (NSD) may affect mucociliary activity (MCA) to varying degrees, depending upon the severity of the deviation. We used rhinoscintigraphy to determine the impact of the various NSD types on MCA.Publication Open Access Synchronous Hepatocellular Carcinoma and Cholangiocellular Carcinoma on F-18-FDG PET/CT(2018-10-01) Erdogan, EZGİ BAŞAK; Turk, HACI MEHMET; Tekce, ERTUĞRUL; Aydin, MEHMET; ERDOĞAN, EZGİ BAŞAK; TÜRK, HACI MEHMET; AYDIN, MEHMETA 43-year-old male patient presented with a mass lesion on the right liver lobe, segment 5, in radiological imaging and elevated alpha-fetoprotein levels (323 ng/mL) compatible with hepatocellular carcinoma (HCC). Positron emission tomography/computed tomography (PET/CT) images showed background level 18F-FDG uptake in the mass lesion. In addition, a secondary focus of increased 18F-FDG uptake was detected on the left liver lobe, segment 2, approximately 1,5 cm in diameter. Histopathological examination revealed HCC in the larger mass lesion with a lower 18F-FDG uptake, and cholangiocellular carcinoma in the smaller mass lesion with a higher 18F-FDG uptake. To our knowledge, this is the first case report of two histopathologically different primary malignant liver tumors in two distinct segments of the liver detected by PET/CT.Publication Open Access New Fetal Dose Estimates from F-18-FDG Administered During Pregnancy: Standardization of Dose Calculations and Estimations with Voxel-Based Anthropomorphic Phantoms(2016-11-01) Zanotti-Fregonara, Paolo; Chastan, Mathieu; Edet-Sanson, Agathe; Ekmekcioglu, Ozgul; Erdogan, EZGİ BAŞAK; Hapdey, Sebastien; Hindie, Elif; Stabin, Michael G.; ERDOĞAN, EZGİ BAŞAKData from the literature show that the fetal absorbed dose from 18F-FDG administration to the pregnant mother ranges from 0.5E-2 to 4E-2 mGy/MBq. These figures were, however, obtained using different quantification techniques and with basic geometric anthropomorphic phantoms. The aim of this study was to refine the fetal dose estimates of published as well as new cases using realistic voxel-based phantoms. Methods: The 18F-FDG doses to the fetus (n = 19; 5-34 wk of pregnancy) were calculated with new voxel-based anthropomorphic phantoms of the pregnant woman. The image-derived fetal time-integrated activity values were combined with those of the mothers' organs from the International Commission on Radiological Protection publication 106 and the dynamic bladder model with a 1-h bladder-voiding interval. The dose to the uterus was used as a proxy for early pregnancy (up to 10 wk). The time-integrated activities were entered into OLINDA/EXM 1.1 to derive the dose with the classic anthropomorphic phantoms of pregnant women, then into OLINDA/EXM 2.0 to assess the dose using new voxel-based phantoms. Results: The average fetal doses (mGy/MBq) with OLINDA/EXM 2.0 were 2.5E-02 in early pregnancy, 1.3E-02 in the late part of the first trimester, 8.5E-03 in the second trimester, and 5.1E-03 in the third trimester. The differences compared with the doses calculated with OLINDA/EXM 1.1 were +7%, +70%, +35%, and -8%, respectively. Conclusion: Except in late pregnancy, the doses estimated with realistic voxelwise anthropomorphic phantoms are higher than the doses derived from old geometric phantoms. The doses remain, however, well below the threshold for any deterministic effects. Thus, pregnancy is not an absolute contraindication of a clinically justified 18F-FDG PET scan.Publication Metadata only Use of PET-CT for the assessment of treatment results in patients with sarcoidosis(2015-04-01) YAKAR, Aysun; YAKAR, Fatih; SEZER, Murat; Bayram, MEHMET; Erdogan, EZGİ BAŞAK; Ozkan, DİDEM; OZCELIK, Hatice K.; TABAK, Levent; BAYRAM, MEHMET; ERDOĞAN, EZGİ BAŞAK; ÖZKAN, DİDEMBackground and aim Sarcoidosis is a multisystem disease of unknown origin. Determining the involvement and the response to the treatment is important. The aim of this study was to identify the effects of methylprednisolone and indomethacine on metabolic activity and pulmonary function test parameters in patients with sarcoidosis.Publication Open Access Radioembolization Treatment for Liver Cancer(2016-04-01) Erdogan, EZGİ BAŞAK; Ozdemir, HÜSEYİN; Aydin, MEHMET; ERDOĞAN, EZGİ BAŞAK; ÖZDEMİR, HÜSEYIN; AYDIN, MEHMETAlthough curative treatment is surgery (resection/transplantation) and for small lesions ablative strategies, in primary liver carcinomas such as hepatocellular carcinoma and cholangiocellular carcinoma, palliative treatment is used for most of these patients because of lack of surgical options. These treatments are regional treatments such as transarterial chemoembolization, radiofrequency ablation, or microwave ablation and systemic treatments such as tyrosine kinase inhibitors. Surgery and chemotherapy are the main treatment options for metastatic liver tumors, particularly in colorectal tumors, although local treatment options are used for these patients. In recent years, transarterial radioembolization with yttrium-90 microsphere has emerged as a local treatment option in primary and metastatic liver tumors. The aim of this treatment is to provide an effective radiation dose distribution for the tumor in the liver tissue and to give the lowest dose in order to not harm the intact liver tissue. Radioembolization has proven to be as effective as other available palliative treatments in primary and secondary liver tumors and is a treatment method that is well tolerated. It has a risk for serious life-threatening complications, although this rate is low. Toxicity can be kept at a minimum with adequate technical and rigorous application in experienced hands and in accordance with multidisciplinarity. It is hoped that the effectiveness of radioembolization is further increased in the future by technological developments, researches on dosimetry, its use along with radiosensitizing agents, and various treatment combinations.